Zuan-Fu Lim, a cancer cell biology graduate student in Patrick Ma’s lab at the WVU Cancer Institute, has received an American Association of Immunologists Young Investigator Award for his first place oral presentation at the 21st annual meeting of the Translational Research Cancer Centers Consortium at Seven Springs, PA.
Lung cancer cells can adopt various mechanisms of resistance to precision therapy. Lim’s research focused specifically on non-small cell lung cancers (NSCLCs) characterized by chromosomal abnormalities in the ALK gene and found that precision therapy targeting the ALK gene may not be effective because molecular drug resistance can emerge in a non-genetic fashion.
Pictured: David Klinke, PhD, of the WVU Cancer Institute congratulates Zuan-Fu Lim, a cancer cell biology graduate student, for winning an American Association of Immunologists Young Investigator Award.
The WVU Cancer Institute is participating in the implementation of a new drug therapy for young patients with leukemia and lymphoma. Chimeric Antigen Receptor (CAR) T-cell therapy, known by the brand name Kymriah®, is a form of immunotherapy that harnesses the patient’s own immune system to fight malignant cancer.
Defense Health Program
The WVU Cancer Institute is applying for a Certificate of Need with the West Virginia Health Care Authority for a mobile lung cancer screening program, which will be called LUCAS. This program would increase access to screening for patients in rural areas and address the growing demand for cancer services in the state.